Last updated: March 7, 2026
What is the Drug with NDC 70792-0809?
The National Drug Code (NDC) 70792-0809 identifies Vaxneuvance, a pneumococcal conjugate vaccine developed by Merck. Approved by the FDA in 2023, Vaxneuvance is designed for adults aged 18 years and older to prevent invasive pneumococcal disease, pneumonia, and acute otitis media.
Current Market Position
Vaxneuvance entered the U.S. vaccine market in early 2023, competing primarily with Pfizer’s Prevnar 13 (PCV13) and Merck’s Pneumovax 23 (PPSV23). The competitive landscape influences pricing strategies and market share.
Market Size
The global adult pneumococcal vaccine market was valued at approximately USD 2 billion in 2022. The U.S. accounted for nearly 70% of this market.
Key Drivers
- Rising pneumococcal disease incidence, especially among seniors.
- Increasing awareness and CDC recommendations expanding adult vaccination.
- COVID-19 pandemic emphasizing vaccine infrastructure and acceptance.
Regulatory and Policy Environment
The CDC Advisory Committee on Immunization Practices (ACIP) recommends PCV13 and PPSV23 for adults aged 65 and older and immunocompromised adults aged 19-64. As a newer vaccine, Vaxneuvance is expected to adhere to similar guidelines, leading to potential market penetration.
Price Strategy and Market Penetration
Initial Pricing
- The wholesale acquisition cost (WAC) for Vaxneuvance was set at USD 150 per dose upon launch, aligning with current adult pneumococcal vaccines.
Pricing Comparison
| Vaccine |
INDICATION |
Price (USD) |
Market Position |
| Vaxneuvance |
Adult 18+ |
150 |
New entrant, comparable to Prevnar 13 |
| Prevnar 13 |
6 weeks-50 years |
160-170 |
Market leader in adult indications |
| Pneumovax 23 |
2 years+, high-risk groups |
85-90 |
Broad coverage, lower price |
Revenue Projections
- Projected U.S. sales for 2023: USD 350 million, driven by uptake among high-risk populations.
- By 2025, sales are expected to reach USD 1 billion, assuming steady adoption and inclusion in CDC recommendations.
Market Challenges
- Competition from established vaccines (Prevnar 13, Pneumovax 23).
- Stricter reimbursement policies from payers.
- Physician and patient acceptance phase, especially for new vaccines.
Price Trends and Future Projections
Market prices tend to stabilize within 1-2 years of launch. However, due to the vaccine's novelty and potential increases in demand, prices could experience slight increases, particularly if supply shortages occur or if new indications are approved.
Price Adjustment Factors
- Payer negotiations.
- Changes in CDC guidelines.
- Competition responses, including potential price cuts.
Long-Term Outlook
Between 2025-2030, Vaxneuvance’s price is forecasted to hover between USD 140-160 per dose in the U.S., aligning with historical patterns for adult conjugate vaccines. Price erosion may occur if biosimilar or interchangeable versions emerge.
Key Takeaways
- Vaxneuvance (NDC 70792-0809) entered the U.S. market in 2023, targeting adult pneumococcal disease prevention.
- Initial pricing at USD 150 per dose positions it competitively against Prevnar 13.
- The U.S. adult pneumococcal vaccine market is projected to grow to USD 3 billion by 2030, driven by increasing vaccine coverage and demographic trends.
- Price stabilization is expected within 1-2 years, with gradual adjustments based on competition, policy, and supply factors.
- Long-term pricing remains linked to health policy, reimbursement strategies, and market uptake.
FAQs
1. What is the primary indication for Vaxneuvance?
Prevention of invasive pneumococcal disease, pneumonia, and otitis media in adults aged 18 and over.
2. How does Vaxneuvance compare in price to other pneumococcal vaccines?
Its initial price of USD 150 per dose aligns closely with Prevnar 13, which ranges from USD 160-170, but it is more expensive than Pneumovax 23.
3. What factors influence the future pricing of Vaxneuvance?
Payer negotiations, CDC guideline updates, market competition, and supply chain factors.
4. What is the projected market share of Vaxneuvance?
Initial market share is expected to be modest (10-15%), increasing to 30-40% within five years, contingent on provider adoption and policy inclusion.
5. What risks could impact the price and market projection?
Emergence of biosimilar manufacturers, shifts in vaccination policy, and reimbursement hurdles.
References
- Centers for Disease Control and Prevention. (2022). Updated adult pneumococcal vaccination recommendations. CDC.
- IQVIA. (2023). Vaccine Market Data and Trends. IQVIA Institute.
- FDA. (2023). Approval document for Vaxneuvance. U.S. Food and Drug Administration.
- MarketWatch. (2023). Global adult pneumococcal vaccine market analysis.
- CDC Advisory Committee on Immunization Practices. (2022). Recommendations for adult vaccination.
Note: All projections are based on current data and market trends, subject to change with regulatory, competitive, and policy developments.
